|
|
Factsheet as on March 28, 2024 |
Factsheet as on March 28, 2024
Structure
Open Ended
Fund Category
Thematic/Sectoral
Fund Manager
Sailesh Raj Bhan
Exit Load
Within 1 Month - 1%
Fund Size
Rs 7125 crs
Launch Date
June 05, 2004
Investment Objective
To generate consistent returns by investing in equity or fixed income securities of pharma and other associated companies.
Market Cap Allocation
Scheme Performance
| 1 Year | 2 Years | 3 Years | 5 Years | |
| Scheme (%) | 59.70 | 22.03 | 20.72 | 23.40 |
| Nifty 500 (%) | 42.39 | 17.45 | 18.52 | 16.08 |
Top 10 Holdings
| Company Name | % of Assets |
| Sun Pharmaceuticals Ind Ltd. | 14.9 |
| Lupin Ltd. | 8.4 |
| Cipla Ltd. | 6.5 |
| Apollo Hospitals Enterprise Ltd. | 5.8 |
| Dr Reddys Laboratories Ltd. | 4.8 |
| Gland Pharma Ltd. | 4.4 |
| Divi Laboratories Ltd. | 4.4 |
| Zydus Lifesciences Ltd. | 4.2 |
| JB Chemicals & Pharmaceuticals Ltd. | 3.4 |
| Abbott India Ltd. | 3.3 |
Year On Year Performance (Scheme V/S Nifty 500)
Ratios:
| Standard Deviation | 15.51 |
| Information Ratio | 0.04 |
| Beta | 0.69 |
| Sharpe Ratio | 0.23 |
Top 10 Sectoral Holdings (%)
SIP Returns
Source: MFI Explorer, Bloomberg.
Please refer to the disclaimer and glossaries
Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390
Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390